State of New Jersey Common Pension Fund D Makes New Investment in ImmunityBio, Inc. $IBRX

State of New Jersey Common Pension Fund D bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) in the 4th quarter, HoldingsChannel reports. The firm bought 112,922 shares of the company’s stock, valued at approximately $224,000.

A number of other hedge funds and other institutional investors have also modified their holdings of IBRX. Heights Capital Management Inc. purchased a new position in shares of ImmunityBio during the 3rd quarter worth $16,152,000. Vanguard Group Inc. grew its holdings in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after purchasing an additional 5,837,898 shares during the period. Woodline Partners LP grew its holdings in shares of ImmunityBio by 53.7% in the third quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock valued at $13,032,000 after purchasing an additional 1,851,854 shares during the period. Two Sigma Investments LP increased its position in ImmunityBio by 224.9% during the third quarter. Two Sigma Investments LP now owns 2,607,860 shares of the company’s stock worth $6,415,000 after purchasing an additional 1,805,297 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its position in ImmunityBio by 347.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,028,921 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Negative Sentiment: Multiple law firms, including Hagens Berman, Rosen, Levi & Korsinsky, Schall, and Faruqi & Faruqi, issued notices about a securities fraud class action against ImmunityBio related to purchases between January 19, 2026 and March 24, 2026, with a key lead-plaintiff deadline of May 26, 2026. Article Title
• Negative Sentiment: The lawsuit centers on allegations that ImmunityBio and its leadership made misleading efficacy claims about Anktiva after the FDA reportedly flagged the statements in a warning letter, raising concerns about regulatory and litigation risk. Article Title
• Neutral Sentiment: Separately, HC Wainwright reportedly cut its FY2028 EPS estimate for ImmunityBio, adding to a cautious analyst backdrop, though the note did not include a major new operating update. Article Title

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total value of $900,750.00. Following the sale, the director owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The SEC filing for this sale provides additional information. Insiders sold a total of 275,000 shares of company stock valued at $2,934,500 in the last quarter. 69.48% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IBRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. HC Wainwright lifted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Finally, BTIG Research set a $12.00 price objective on ImmunityBio in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Price Performance

Shares of IBRX opened at $8.11 on Tuesday. ImmunityBio, Inc. has a 1-year low of $1.95 and a 1-year high of $12.43. The stock has a market cap of $8.49 billion, a PE ratio of -9.54 and a beta of 0.02. The firm has a 50-day simple moving average of $7.95 and a two-hundred day simple moving average of $5.26.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The firm had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.